Drug Trial Radar · NCT05818683
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 26, 2023
Primary completion
Aug 31, 2027
Study completion May 23, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Metastatic Hormone-sensitive Prostate Cancer
Interventions
PasritamigDrug
Pasritamig will be administered.
CetrelimabDrug
Cetrelimab will be administered by intravenous infusion.
CabazitaxelDrug
Cabazitaxel will be administered by intravenous infusion.
DocetaxelDrug
Docetaxel will be administered by intravenous infusion.
ApalutamideDrug
Apalutamide will be administered orally.
EnzalutamideDrug
Enzalutamide will be administered orally.
DarolutamideDrug
Darolutamide will be administered orally.
Abiraterone acetate plus prednisone (AAP)Drug
Abiraterone acetate plus prednisone (AAP) will be administered orally.
Lutetium Lu-177 vipivotide tetraxetanDrug
Lutetium Lu-177 vipivotide tetraxetan will be administered intravenously.
JNJ-101556143Drug
JNJ-101556143 will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 21 days after first dose of combination agent
- Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 2 years 11 months
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Start Midwest
Grand Rapids, Michigan · Recruiting
Perlmutter Cancer Center at NYU Langone Brooklyn
Brooklyn, Mississippi · Recruiting
Washington University School Of Medicine
St Louis, Missouri · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania · Recruiting
Icon Cancer Centre Kurralta Park
Adelaide, Australia · Recruiting
Macquarie University
Macquarie Park, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Hosp Univ Vall D Hebron
Barcelona, Spain · Recruiting
Hosp Univ Fund Jimenez Diaz
Madrid, Spain · Recruiting
Hosp. Univ. 12 de Octubre
Madrid, Spain · Recruiting
Hosp Univ Hm Sanchinarro
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.